Ranit Schmelzer, 202.538.1065, firstname.lastname@example.org
Washington, DC – The Global CEO Initiative on Alzheimer’s Disease (CEOi) today announced that the Roche Group, a leading global healthcare company, will join the CEOi as part of its ongoing effort to advance innovations in research and drug development to stop Alzheimer’s by 2025. Roche is at the forefront of Alzheimer’s research and drug development, and is a recognized leader in innovation and developing differentiated medicines.
Every four seconds, another person somewhere in the world is diagnosed with Alzheimer’s or related dementia. It is the only disease in the top 10 with no disease-modifying treatment, or cure. Without a drug to slow the progression of the disease, the prevalence of Alzheimer’s, which already costs the world $605 billion annually, is projected to triple from 44 million to 135 million people by 2050, leaving an unprecedented number of people reliant on the care of others.
“Roche is a leader in the effort for early detection, prevention, diagnosis, and treatment of diseases and is deeply involved in the Alzheimer’s effort,” said George Vradenburg, Convener of the CEOi and Chairman of USAgainstAlzheimer’s. “I’m so pleased that Roche has partnered with us on the fight against this dreadful disease. Without innovations in research and drug development, faster clinical trials, and an expanded diversity of drug targets, we have little hope of finding a cure.”
By working together with leading private sector businesses and in partnership with leading non-governmental organizations and governments, the CEOi identifies and pursues research, therapy development, financing, and care delivery projects of the highest priority that, when executed, can transform the global fight to stop Alzheimer’s disease. The CEOi members include AC Immune, Bank of America, Banner Health, General Electric, Home Instead, Janssen, Lilly, Merck, Nestle Health Science, Pfizer, Sanofi, and Takeda.
“We are proud to be an active partner in this important global initiative that supports the transformation of the management of Alzheimer’s disease,” said Daniel O’Day, Chief Operating Officer of the Pharmaceuticals Division of Roche. “The CEOi offers an unprecedented level of collaboration to advance and accelerate research, raise awareness, and ultimately bring better medicines to people living with this devastating disease.”
The Global CEO Initiative on Alzheimer’s Disease (CEOi) is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. The CEO Initiative seeks to partner with public leaders to transform the disease from a social, health, and economic crisis into an opportunity for healthy aging and innovation in research and care. The CEO Initiative believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. Learn more at: www.ceoalzheimersinitiative.org